Companies · Biotechnology
Denver · CO, USA; Cambridge, MA, USA · Biotechnology · founded 2021 · https://www.aoadx.com/
Diligence memoA one-page analyst read on AOA DX Inc. — recommendation, valuation, rhythm, risks.→AOA DX Inc. looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
AOA DX Inc. is one of 4293 Biotechnology companies tracked from Denver, CO, USA; Cambridge, MA, USA, on record since 2021. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Blood Test for Early Detection of Ovarian Cancer
AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 78% of sector peers (real $). Modeled value above 37% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #70 of 94.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| MarvelBiome, Inc. | Series B | $54.9M | $163.2M | 2.11× |
| Iantrek, Inc. | Series B | $58.2M | $152.4M | 1.97× |
| Dualitas Therapeutics, Inc. | Series B | $32.6M | $150.4M | 1.94× |
| Antares Therapeutics, Inc. | Series B | $70.0M | $149.7M | 1.93× |
| OrthoBio Therapeutics, Inc. | Series B | $31.4M | $147.5M | 1.90× |
| Medcura, Inc. | Series B | $40.9M | $145.0M | 1.87× |
| Neurolutions Inc | Series B | $26.5M | $144.9M | 1.87× |
| Renasant Bio, Inc. | Series B | $55.5M | $144.0M | 1.86× |
| Caldera Therapeutics, Inc. | Series B | $37.5M | $139.2M | 1.80× |
| VitriVax, Inc. | Series B | $29.4M | $136.9M | 1.77× |
| DiaMedica Therapeutics Inc. | Series B | $110.4M | $136.3M | 1.76× |
| OmniAb, Inc. | Series B | $30.0M | $130.5M | 1.68× |
| AOA DX Inc. this company | Series B | $38.7M | $33.7M | 0.43× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.5M | 2021-02-26 | $12.5M | $77.2M | 90% |
| Seed | $2.6M | 2021-11-03 | $13.2M | $55.8M | 90% |
| Series B | $23.6M | 2023-07-11 | $131.2M | $256.0M | 90% |
| Series B | $1.8M | 2024-12-05 | $10.3M | $10.9M | 90% |
| Series B | $8.1M | 2025-10-01 | $44.9M | $33.7M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| John Friedman | — | 8 other | 2023-07 |
| Surbhi Sarna | — | 1 other | 2021-11 |
| Abigail James Mcelhinny | — | — | 2024-12 |
| Alexander Fisher | — | — | 2021-11 |
| Alexander James Fisher | — | — | 2021-02 |
| Anna Milik Jeter | — | — | 2021-02 |
| Oriana Papin-Zoghbi | — | — | 2023-07 |
| Oriana Zoghbi-Harb | — | — | 2021-02 |
AOA DX Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Nora Therapeutics, Inc. | Biotechnology | Series B | $38.3M | $39.7M | same sector · same stage |
| Lysosomal Therapeutics, Inc. | Biotechnology | Series B | $38.0M | $39.7M | same sector · same stage |
| Unigene Laboratories Inc | Biotechnology | Series B | $37.8M | $29.8M | same sector · same stage |
| Abpro Corp | Biotechnology | Series B | $42.4M | $37.6M | same sector · same stage |
| Eleven Biotherapeutics, Inc. | Biotechnology | Series B | $43.3M | $39.5M | same sector · same stage |
| i2O Therapeutics, Inc. | Biotechnology | Series B | $43.9M | $35.0M | same sector · same stage |
| VIRxSYS Corp | Biotechnology | Series B | $44.6M | $39.7M | same sector · same stage |
| SIRPant Immunotherapeutics, Inc. | Biotechnology | Series B | $32.4M | $28.7M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Aortic Innovations LLC | Biotechnology | Seed | $71.9M | 74% |
| Aortica Corp | Biotechnology | Series A | $37.1M | 74% |
| Early Stage Cancer Detection, Inc. | Biotechnology | Pre-Seed | $7.4M | 73% |
| Delee Corp Blood testing device for early diagnosis of cancer and treatment… | Biotechnology | Seed | $52.2M | 73% |
| A-Alpha Bio, Inc. | Biotech / Pharma | Series B | $465.2M | 72% |
| Hera Testing Laboratories, Inc. | Biotechnology | Seed | $45.4M | 72% |
| Ora Biomedical, Inc. | Biotechnology | Pre-Seed | $4.4M | 72% |
| Clear Gene Our tests help eradicate cancer by telling doctors whether they got… | — | — | — | 72% |
See where AOA DX Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at AOA DX Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.